Insmed Stock

Insmed EBITDA per Employee

The EBITDA per Employee of Insmed (INSM) as of Aug 10, 2026 is -2.28 M USD. In the previous year, EBITDA per Employee was -1.57 M USD — a change of 44.85% (lower).

EBITDA per Employee

-2.28 MUSD

YoY

44.85%

Last updated:

EBITDA per Employee of Insmed is 2026 -2.28 M USD. EBITDA per Employee of Insmed was 2025 -1.57 M USD. It decreases by 44.85% lower compared to the previous year.
Access this data via the Eulerpool API

Insmed Stock analysis

What does Insmed do? Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insmed stock

EBITDA per Employee of Insmed is -2.28 M USD in 2026.

EBITDA per Employee of Insmed changed from -1.57 M USD to -2.28 M USD, representing a 44.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Insmed since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Insmed historically and in real time.

Access this data via the Eulerpool API

Workforce — Insmed

All Key Metrics — Insmed